Rocket Pharmaceuticals (RCKT) to Announce Quarterly Earnings on Thursday

Rocket Pharmaceuticals (NASDAQ:RCKT) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Rocket Pharmaceuticals to announce earnings of $0.86 per share and revenue of $0.2220 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01). During the same period last year, the company posted ($0.56) EPS. On average, analysts expect Rocket Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rocket Pharmaceuticals Stock Up 0.9%

RCKT stock opened at $3.44 on Wednesday. The stock has a market cap of $375.61 million, a PE ratio of -1.84 and a beta of 0.47. The firm’s 50-day simple moving average is $3.29 and its 200 day simple moving average is $3.62. Rocket Pharmaceuticals has a fifty-two week low of $2.53 and a fifty-two week high of $5.45. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.08.

Insider Transactions at Rocket Pharmaceuticals

In other news, CEO Gaurav Shah sold 55,684 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $3.09, for a total value of $172,063.56. Following the completion of the transaction, the chief executive officer directly owned 1,061,724 shares in the company, valued at $3,280,727.16. This trade represents a 4.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sarbani Chaudhuri sold 17,650 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $3.84, for a total transaction of $67,776.00. Following the transaction, the insider owned 267,510 shares in the company, valued at $1,027,238.40. This represents a 6.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 83,733 shares of company stock valued at $275,307 in the last quarter. 21.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Rocket Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC raised its holdings in shares of Rocket Pharmaceuticals by 148.4% in the 1st quarter. AQR Capital Management LLC now owns 163,622 shares of the biotechnology company’s stock worth $1,091,000 after purchasing an additional 97,758 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Rocket Pharmaceuticals by 121.8% during the 1st quarter. Millennium Management LLC now owns 747,147 shares of the biotechnology company’s stock valued at $4,983,000 after acquiring an additional 410,238 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Rocket Pharmaceuticals in the first quarter worth $189,000. Goldman Sachs Group Inc. raised its holdings in shares of Rocket Pharmaceuticals by 24.0% during the first quarter. Goldman Sachs Group Inc. now owns 995,690 shares of the biotechnology company’s stock worth $6,641,000 after acquiring an additional 192,905 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Rocket Pharmaceuticals by 1.8% during the second quarter. Geode Capital Management LLC now owns 2,030,891 shares of the biotechnology company’s stock worth $4,976,000 after acquiring an additional 36,847 shares in the last quarter. Institutional investors and hedge funds own 98.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on RCKT. Weiss Ratings upgraded shares of Rocket Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Wall Street Zen raised Rocket Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Chardan Capital reiterated a “buy” rating and set a $11.00 price objective on shares of Rocket Pharmaceuticals in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Rocket Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.71.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.